A B S T R A C T Histamine, beta-adrenergic amines, and prostaglandins inhibited hemolytic plaque formation by splenic leukocytes from immunized mice. The same agents had previously been shown to prevent both the IgE-mediated release of histamine from human basophils and the immunologically specific cytolytic activity of murine lymphocytes, through stimulation of the production of cyclic AMP in leukocytes. We therefore tested the hypothesis that cyclic AMP might mediate an inhibitory effect of these drugs by comparing the ability of these agents to inhibit plaque formation with their effects on cyclic AMP accumulation in leukocytes. In splenic cells from three mouse strains, the dose-dependent effects of these agents on cyclic AMP correlated with their inhibition of plaque formation. Beta-but not alpha-adrenergic agonists were effective in both systems, and the effects of isoproterenol were inhibited by propranolol. Histamine was approximately equipotent with isoproterenol in both systems. Two prostaglandins (Ei and E2) were effective in both systems, but prostaglandin F2. was not. Dibutyryl cyclic AMP, a lipid-soluble analog of the endogenous nucleotide, inhibited plaque formation by cells of all three strains. Theophylline, an inhibitor of cyclic AMP degradation, inhibited plaque formation slightly, but potentiated the effects of histamine, isoproterenol, and the prostaglandins on both cyclic AMP accumulation and plaque formation. Finally, cholera enterotoxin, a potent activator of adenyl cyclase, produced a delayed inhibition of plaque formation and a parallel increase in leukocyte cyclic AMP content; both effects of the toxin were blocked by canine antitoxin. These results suggest that leukocyte cyclic AMP may act as a "second messenger" to suppress plaque formation in vitro. The inhibitory effects of hormones and
IgE-mediated release of histamine from human basophils and the immunologically specific cytolytic activity of murine lymphocytes, through stimulation of the production of cyclic AMP in leukocytes. We therefore tested the hypothesis that cyclic AMP might mediate an inhibitory effect of these drugs by comparing the ability of these agents to inhibit plaque formation with their effects on cyclic AMP accumulation in leukocytes. In splenic cells from three mouse strains, the dose-dependent effects of these agents on cyclic AMP correlated with their inhibition of plaque formation. Beta-but not alpha-adrenergic agonists were effective in both systems, and the effects of isoproterenol were inhibited by propranolol. Histamine was approximately equipotent with isoproterenol in both systems. Two prostaglandins (Ei and E2) were effective in both systems, but prostaglandin F2. was not. Dibutyryl cyclic AMP, a lipid-soluble analog of the endogenous nucleotide, inhibited plaque formation by cells of all three strains. Theophylline, an inhibitor of cyclic AMP degradation, inhibited plaque formation slightly, but potentiated the effects of histamine, isoproterenol, and the prostaglandins on both cyclic AMP accumulation and plaque formation. Finally, cholera enterotoxin, a potent activator of adenyl cyclase, produced a delayed inhibition of plaque formation and a parallel increase in leukocyte cyclic AMP content; both effects of the toxin were blocked by canine antitoxin. These results suggest that leukocyte cyclic AMP may act as a "second messenger" to suppress plaque formation in vitro. The inhibitory effects of hormones and INTRODUCTION Histamine, catecholamines, and prostaglandins have recently been found capable of modulating the expression of both immediate and cell-mediated hypersensitivity in vitro. These endogenous vasoactive hormones inhibit both the IgE-mediated release of histamine and other mediators of inflammation from human basophils, human and monkey lung, and rat mast cells (1) (2) (3) (4) (5) (6) and the immunologically specific cytolytic activity of mouse splenic lymphocytes (6, 7). All three classes of hormones appear to produce their inhibitory effects by stimulating the production of cyclic AMP, which acts in leukocytes and mast cells as an inhibitory "second messenger" (8) . The Cyclic AMP, however, was measured in a heterogenous mixed population of spleen cells, of which only a small percentage (maximum 1%) actually released antibody specific for SRC. The hypothesis that intracellular cyclic AMP inhibited plaque formation was therefore tested with cholera enterotoxin, which produces a delayed rise in cyclic AMP in every mammalian tissue so far tested (9) . The toxin has recently been used as a pharmacologic tool to help confirm the role of cyclic AMP in models of immediate and delayed hypersensitivity (6 In preliminary experiments aliquots of the diluted incubates containing both cells and drugs were added to plain agar plates. When large numbers of samples were read, it was noted that a delay in reading PFC resulted in progressive loss of inhibition by the drugs, particularly when they had been added to the preincubates at low concentrations. Diluting the incubate before plating apparently critically lowered the concentrations of some drugs (e.g., dibutyryl cyclic AMP) so that they were ineffective. Therefore, in all our experiments, drugs were added to both the top and bottom layer of agarose at concentrations precisely matching those in original incubates. Tests of incubates of cells in media containing drugs by the Trypan blue dye method revealed that 85-92% of cells remained viable for the entire period, including the plate-reading time. Viability of control cells was not significantly different from those in experimental tubes.
To determine whether any drugs used in the plaque assay could directly interfere with the function of complement, the following test was performed in quadruplicate, with 1-2 magnitudes higher concentrations of each drug than were used in the actual plaque inhibition experiments. Serial dilutions of goat anti-SRC were made from 1: 10 to 1: 160. Aliquots of each dilution (50 jul) were spotted on the Petri dishes containing the drug, agar, and all other components used for the assay, except for the spleen cells.
After 1 h at 37'C, complement was added and 2 h later lysis of the SRC was checked. None of the drugs influenced the lysis of SRC, even when complement concentrations were 20-40 times less than those used in the actual plaque assays (with spleen cells). Rosette formation assays were performed by the method of Shearer and Cudkowitz (13) .
Leukocyte cyclic AMP. Leukocytes in MEM (12-50 X 106 cells/ml) were exposed to drugs for 15 min, unless otherwise noted. Incubations were terminated by centrifuging the cells at 800 g for 1 min (0'C), after which the supernatant fluid was discarded and the cell button was resuspended in 1.2 ml 5% trichloroacetic acid (TCA). The TCA was extracted with ether and cyclic AMP assayed by the competition-binding assay of Gilman (14), modified as previously described (2) . All values reported are the means of duplicate or triplicate drug incubations, differing by not more than 8%o. We were not able to measure the cyclic AMP concentrations of the supernates from the incubations. Such studies are now in progress.
Materials. Prostaglandins were obtained from Dr. Peter Ramwell (Alza Corporation, Palo Alto, Calif.) and Dr. John Pike (The Upjohn Co., Kalamazoo, Mich.). Purified cholera enterotoxin, prepared as previously described (15) (16) .
RESULTS
Histamine and beta-adrenergic catecholamines produced a dose-dependent inhibition of plaque formation by splenic leukocytes from BALB/BL mice immunized with 14 SRC (Fig. 1) . In order to test the hypothesis that cyclic AMP was related to that inhibition, we compared the ability of biogenic amines (histamine and adrenergic amines), prostaglandins, and cholera enterotoxin to stimulate accumulation of cyclic AMP and inhibit plaque formation, in parallel experiments with splenic cells from three mouse strains (BALB/BL, BALB/c, and C57BL/6). Each of the agents has been shown to elevate leukocyte cyclic AMP content by stimulation of adenyl cyclase (2, (6) (7) (8) 17) , the enzyme which converts ATP to cyclic AMP. In other experiments we tested the effects of both theophylline, which inhibits enzymatic degradation of cyclic AMP, and dibutyryl cyclic AMP, which is thought to mimic the effect of the endogenous nucleotide.
Our results pertain to formation of direct (19S) (Table I) .
In four experiments none of the drug classes inhibited rosette formation, even when the same concentrations maximally inhibited plaque formation.
Biogenic amines. In all three mouse strains, histamine and the beta-adrenergic catecholamines inhibited plaque formation (Fig. 1 , representative data indicating rank order of drug potency, Table II ) and stimulated accumulation of cyclic AMP in splenic leukocytes (Table  III) . Isoproterenol was in general slightly more potent than histamine, both at inhibiting plaque formation and elevating cyclic AMP content of the cells. In one parental strain (BALB/c), higher concentrations of both amines were required to inhibit plaque formation significantly (Table II) . The cyclic AMP data (Table III) are not sufficient to document a parallel lack of nucleotide accumulation in BALB/c cells with these two agents.
The relative potencies of the adrenergic agents in all three strains suggested that they produce their effects on cyclic AMP and plaque formation through a betaadrenergic receptor. The rank order of these amines in inhibiting plaque formation in BALB/BL was exactly parallel to that for inhibition of histamine release from human basophils (2) and for beta-adrenergic effects in other systems (18) : Isoproterenol and epinephrine were almost equipotent, norepinephrine was less potent, and the predominantly alpha-adrenergic agent, phenylephrine, was a very weak inhibitor (Fig. 1) . In all three mouse strains isoproterenol, a predominantly beta-adrenergic agonist, was considerably more potent than phenylephrine as an inhibitor of plaque formation (Table II) or stimulator of nucleotide accumulation (Table III).
Cyclic AMP and Cellular Antibody 15 A beta-adrenergic effect should be blocked by a specific beta-adrenergic antagonist, such as propranolol.
In two mouse strains, C57BL and BALB/BL, propranolol completely prevented the effects of isoproterenol (but not histamine) on cyclic AMP accumulation (Table III) and partially blocked isoproterenol's inhibition of plaque formation (Table II (Fig. 2) . PGF2. produced no effect on cells from C57BL and BALB/c spleens. A relatively high concentration (1 X 10' M) of PGF2. produced a slight rise in cyclic AMP in BALB/BL spleen cells (comparable to the effects of histamine or isoproterenol) and significantly inhibited plaque formation. The pattern of prostaglandin effects on spleen cells from these three mouse strains parallels effects documented in mixed human leukocytes, purified human lymphocytes, human platelets, and other tissues (2, 20, 21) : The E prostaglandins are generally potent stimulators of adenyl cyclase, while the F prostaglandins are generally inactive.
Since propranolol failed to block the effect of PGE1 on cyclic AMP accumulation (Table III) , it is likely that the prostaglandins produce their effects through a receptor other than one responsive to beta-adrenergic agents, as has been suggested for human leukocytes (2, 22) . For this reason, and because neither the prostaglandins nor the biogenic amines produced complete in- likely that the majority of PFCs possess receptors to each of the three drug classes.
Cholera enterotoxin. The choleragenic enterotoxin of Vibrio cholerae produces a delayed, dose-dependent activation of adenyl cyclase and accumulation of cyclic AMP in every mammalian tissue so far tested, including Balb/BL human leukocytes and murine splenic lymphocytes (6, 9, 17) . The enterotoxin's apparently specific effect on adenyl cyclase, its characteristically delayed effect, and the availability of a specific antitoxin have made it a useful pharmacologic tool for testing hypotheses relating cyclic AMP to function of basophils, neutrophils, and lymphocytes (6, 10) . When preincubated for 90 min with spleen cells from C57BL, BALB/c, and BALB/BL mice, cholera enterotoxin (10 ng/ml) inhibited subsequent plaque formation by 42-59% (Fig. 3) . By this time, it also produced an increase in cyclic AMP content of splenic leukocytes. A specific canine antiserum (1:1,000 dilution) to the toxin prevented both the rise in cyclic AMP and the inhibition of plaque formation at 90 min. A short period (10 min) of preincubation with the toxin failed to affect either cyclic AMP or plaque formation. At these concentrations the toxin did not af-3 E fect cell viability. (Table II) .
The effects of theophylline and other methylxanthines are often adduced as evidence for an effect of cyclic AMP in tissues, since these compounds inhibit the phosphodiesterase that inactivates intracellular cyclic AMP by converting it to 5'-AMP. Theophylline would therefore be expected to potentiate the effects of agents that stimulate adenyl cyclase, in regard to both cyclic AMP content and cell function. Theophylline by itself (1 X 10' M) produced little effect on cellular cyclic AMP (Fig. 4) or on plaque formation (Table I) by mouse spleen cells. However, it did potentiate the effects of histamine, isoproterenol, and the prostaglandins on cyclic AMP accumulation (Fig. 4 ) and plaque formation (Table I) .
DISCUSSION
These experiments demonstrate that certain endogenous vasoactive hormones can inhibit plaque formation by leukocytes from three mouse strains. The same hormones in vitro inhibit expression of two other immunologic responses, IgE-mediated immediate hypersensitivity (1) (2) (3) (4) (5) (6) and cell-mediated (delayed) hypersensitivity (6, 9) , as well as the transformation of human lymphocytes by phytohemagglutinin (20) , and the release of lysosomal hydrolases from phagocytic neutrophils (17) . Since most of these inhibitory effects appear to be mediated by intracellular cyclic AMP, the experiments reported here were aimed at as critical an evaluation of the role of the nucleotide in inhibiting antibody release as possible. The evidence that cyclic AMP might mediate the hormonal inhibition of antibody in the in vitro system is as follows:
The dose-dependent hormonal stimulation of cyclic AMP accumulation in splenic leukocytes correlated with hormonal inhibition of plaque formation. In each mouse strain the order of potency of both the adrenergic agonists and the prostaglandins was the same for measurement of both cyclic AMP accumulation and inhibition of plaque formation. Propranolol prevented the effect of isoproterenol on cyclic AMP and, in two of the three strains, partially prevented isoproterenol's inhibition of plaque formation. The full interpretation of the effects of propranolol are not possible since the drug itself inhibited plaque formation to some extent, although independently of changes in intracellular cyclic AMP.
A cyclic AMP analog, dibutyryl cyclic AMP, inhibited plaque formation in all three strains.
Theophylline (24) . Second, all three classes of hormones used in this study inhibit immunologically specific cytolysis of target cells by murine spleen cells (6, 7) in a model that probably correlates with cell-mediated immunity (delayed hypersensitivity). Two of these three immunologic functions (e.g., cell-mediated immunity and antibody production) are almost surely performed by different cells. Nonetheless, the presence of receptors for amines or prostaglandins or both, acting to regulate the cyclic AMP system, probably is common to cells performing all three functions.
We have not established the details of the biochemical mechanism by which these endogenous hormones and cyclic AMP might regulate immunological function, nor the physiologic significance of these effects in vivo. The almost universally inhibitory effect of cyclic AMP on leukocyte function (8) (26, 27) . The impressive interweaving of inflammatory and immune responses in both host defenses and the causation of many diseases suggests, however, that servomechanisms might exist. Both endogenous vasoactive hormones and cyclic AMP may eventually prove to play important roles in controlling or coordinating phenomena as diverse as inflammation, allergy, and humoral and cell-mediated immunity.
